Now Reading
$10 million gift from Zelma and Bill Reid launches MD Anderson’s bid to stop disease before it starts
Dark Light

$10 million gift from Zelma and Bill Reid launches MD Anderson’s bid to stop disease before it starts

Pancreatic cancer gives very little warning.

It grows deep in the abdomen, usually without symptoms, and by the time most people feel something is wrong, the disease has often spread.

Zelma and Bill Reid have spent nearly 30 years supporting one of the world’s leading cancer centers.

Their newest gift goes after that silence directly.

Recently, the University of Texas MD Anderson Cancer Center announced a $10 million commitment from the Reids to create the Pancreatic Cancer High-Risk Interception Program.

The program is meant to find the disease in people most likely to develop it and to step in early enough that cancer either never forms or is caught while it can still be cured.

It is the largest chapter so far in a relationship that goes back three decades.

More than ten years ago, the couple was already listed in MD Anderson’s Anderson Assembly, the society for donors who have given $1 million or more.

Zelma Reid described the gift as the result of long admiration rather than a sudden decision.

“For nearly 30 years, we have admired UT MD Anderson’s commitment to advancing research and improving patient care,” she said.

“We are inspired by the work being led by Drs. Kim, Bhutani, and McAllister, and we are honored to support a program that has the potential to intercept pancreatic cancer earlier and save more lives. We hope this investment helps create new possibilities for patients and families for generations to come.”

The numbers make the need clear.

This year, about 67,530 Americans will be diagnosed with pancreatic cancer and about 52,740 will die from it.

It is the third-leading cause of cancer death in the United States, even though it ranks much lower by number of cases.

Only 13 percent of patients are alive five years after diagnosis, and that figure has not moved for three straight years, even as survival across all cancers combined has reached 70 percent.

Timing is what separates outcomes.

When the cancer is found while it is still inside the pancreas, five-year survival rises to about 44 percent.

Once it has spread to distant organs, survival drops to roughly 3 percent.

Only about one patient in six is diagnosed at the early, localized stage.

The program is designed to change those odds.

It does not wait for symptoms.

It starts with the people whose risk is already known to be higher: people with inherited genetic mutations, people with several relatives who have had the disease, people whose scans show pancreatic cysts, and older adults with newly diagnosed diabetes, which researchers now see as a possible early warning sign.

For these patients, the program offers expert evaluation, advanced imaging, molecular testing, and coordinated follow-up.

It also brings in AI-driven risk assessment, next-generation DNA testing and surveillance tailored to each person.

The gift centers on three physicians whose specialties cover the full path from risk to treatment.

Dr. Florencia McAllister, a professor of gastrointestinal medical oncology and genetics, came to MD Anderson from Johns Hopkins to build the institution’s pancreatic cancer high-risk clinic, which she has directed for more than a decade.

Her clinic sees patients’ relatives.

Every MD Anderson pancreatic cancer patient receives genetic testing, and about one in ten carries a mutation that raises risk, so their parents, siblings, and children need answers too.

McAllister also co-leads MD Anderson’s Pancreatic Cancer Moon Shot, and her lab works on vaccines and immune-based approaches to stop the disease in high-risk people before it takes hold.

Dr. Michael P. Kim, an associate professor of surgical oncology, runs MD Anderson’s pancreatic cyst clinic.

His field holds one of the quiet dilemmas of modern medicine.

Because so many people now get CT and MRI scans, pancreatic cysts turn up all the time.

Kim estimates that 10 to 20 percent of people over 60 have one.

Most are harmless, but some are true precursors to cancer, and telling them apart is difficult.

Kim’s research looks for the genetic and molecular signals that show which cysts are dangerous.

Dr. Manoop S. Bhutani, a professor of gastroenterology and hepatology, brings deep expertise in endoscopic ultrasound, which lets physicians examine the pancreas closely, sample suspicious tissue and confirm a diagnosis.

For patients, the most important promise may be precision in both directions.

The program aims to tell, with real accuracy, whether a given cyst is likely to become cancer.

That means intervening when it matters and sparing people major pancreatic surgery they don’t need.

“The ultimate goal is to intercept pancreatic cancer development or to initiate treatment earlier in the disease process, when patients have the best chance for successful outcomes,” Kim said.

“This gift will allow us to expand our research efforts, strengthen collaborations across disciplines, and accelerate promising strategies to identify and intercept pancreatic cancer before it becomes life-threatening. We are incredibly thankful to the Reids for making this work possible.”

The team has already shown what this kind of watchfulness can do.

In one published case, a man in his early fifties with an unusual form of Peutz-Jeghers syndrome came to the high-risk clinic for routine surveillance.

The inherited condition raises pancreatic cancer risk more than a hundredfold.

He had no symptoms, but annual imaging found a lesion, and he was treated within the window when surgery can still cure.

The Reids’ gift is meant to make that outcome ordinary rather than exceptional.

The program also looks ahead.

A shared bank of biospecimens and data will support new research into early detection, giving scientists the samples and long-term records they need to confirm which blood markers, genetic signatures and imaging features truly predict disease.

A dedicated training program will prepare the next generation of physicians and scientists in pancreatic cancer prevention, which is still a young specialty.

MD Anderson also plans to widen access to specialized screening, so more high-risk families reach expert care before cancer appears.

Dr. Jeffrey E. Lee, MD Anderson’s president ad interim, said the gift reflects philanthropy’s distinct power in medicine.

“Philanthropic investments like this create opportunities to accelerate discoveries and pursue bold approaches to some of the most challenging cancers we face,” he said.

“We are deeply grateful to Zelma and Bill Reid for their generosity and enduring commitment. Their support will help advance innovative research aimed at intercepting pancreatic cancer earlier, when we have the greatest opportunity to improve outcomes for patients.”

When the gift was celebrated in Houston, the Reids stood with the three physicians who will lead the program and with Dr. Matthew H.G. Katz, chair of surgical oncology and one of the country’s leading pancreatic cancer surgeons.

The scene captured the heart of the gift: a couple who has given patiently for three decades, backing a team that hopes to make the hardest part of pancreatic cancer care, the late diagnosis, something future families never have to face.

For the Reids, the measure of success will not be a building or a name on a wall.

It will be people who never get the diagnosis at all and families who learn they were at risk in time to do something about it.

 

Photo: Florencia McAllister, M.D., William Reid, Michael P. Kim, M.D., Zelma Reid, Manoop S. Bhutani, M.D., and Matthew H.G. Katz, M.D., celebrate the Reids’ $10 million gift

© 2026 Lifestyles Magazine International. All Rights Reserved.